Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04143152 · ClinicalTrials.gov registry record

Pancreatic Cancer Biomarker Study

A clinical trial of Pancreatic Adenocarcinoma, sponsored by Van Andel Research Institute.

Active
Registry status
300
Enrollment target
1
Study location

NCT04143152 is a study of Pancreatic Adenocarcinoma that is active but no longer recruiting, run by Van Andel Research Institute. The registered enrollment target is 300 participants, below the 99,460-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04143152, a study of Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by Van Andel Research Institute.

ACTIVE NOT RECRUITING
Registry status
300 participants
Enrollment target
1
Study location

Study Summary

This is a non-treatment, blood collection study to evaluate biomarker panels for the diagnosis and prognosis of pancreatic cancer.

Conditions Studied

Study Locations (1)

Michigan

  • Mercy Health Saint Mary's Hospital - Grand Rapids

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2021-01-01
Est. Completion 2024-10-31

Sponsor

Van Andel Research Institute

3 total trials

What the Registry Record Tells You About NCT04143152

The ClinicalTrials.gov registry entry for NCT04143152 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,460-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is Van Andel Research Institute, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions.

NCT04143152 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT04143152 about?

NCT04143152 is a clinical study titled "Pancreatic Cancer Biomarker Study". This is a non-treatment, blood collection study to evaluate biomarker panels for the diagnosis and prognosis of pancreatic cancer.

What is the current status of trial NCT04143152?

This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2021-01-01. Estimated completion is 2024-10-31.

What conditions does trial NCT04143152 study?

This clinical trial studies the following conditions: Pancreatic Adenocarcinoma.

Who is sponsoring clinical trial NCT04143152?

This trial is sponsored by Van Andel Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04143152 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.